Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab + Avelumab in Advanced NSCLC
NCT03268057Phase 2Completed
- Sponsor
- Vaccinex, Inc.
- Start
- Oct 2017
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pepinemab in non-small cell lung cancer (NSCLC), sponsored by Vaccinex, Inc. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events at 2 years. Started Oct 2017; status: completed.
02
Drugs
pepinemab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03268057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03268057.